Navigation Links
Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Date:6/2/2009

MOUNTAIN VIEW, Calif., June 2 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that Qnexa data will be featured in two podium presentations during the 69th Scientific Sessions of the American Diabetes Association (ADA), being held from June 5-9, 2009 in New Orleans, Louisiana. Previous studies have shown significant weight loss with Qnexa treatment. Both podium presentations will highlight the benefit of weight loss and the corresponding positive impact on type 2 diabetes. Data from the phase 3 EQUATE trial (OB-301) shows that weight loss with Qnexa stops the progression of type 2 diabetes in obese, non-diabetic patients. The results of a year-long phase 2 diabetic study, DM-230, demonstrate that weight loss with Qnexa can significantly lower blood sugar in type 2 diabetics.

"Obesity and type 2 diabetes, which are inextricably linked, are growing at epidemic proportions worldwide and physicians need new, more effective treatment options for the millions of patients at risk," commented Leland Wilson, president and chief executive officer of VIVUS. "In clinical studies to date, Qnexa has demonstrated significant impact on patients' weight, glucose levels, HbA1c and other critical cardiovascular risk factors, in patients with and without diabetes. We are delighted that Qnexa data from our previously reported phase 3 obesity study and our previously reported year-long diabetes study have been selected for podium presentations at the ADA annual meeting."

Details for the two oral podium presentations of Qnexa data follow:

Date and Time: Saturday, June 6, 2009, 4:00-6:00 P.M.

Session: Novel Diabetes Treatments in Development in Humans'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
6. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
7. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
8. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
9. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
10. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
11. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , , Primary efficacy endpoint has been me...t endometrial cancer, , QUEBEC CITY, Nov. 24 ...SDAQ: AEZS ; TSX: AEZ) (the "Company"), a global ...rapy and oncology, today announced positive effica...otoxic peptide conjugate, AEZS-108 (formerly AN-15...
(Date:11/24/2009)... , DUBLIN, November 24 /PRNewswire-FirstC... global specialty biopharmaceutical company, today...pean Medicines Agency for,velaglucerase alfa, the ...t,for the treatment of Type 1 Gaucher disease. Thi...rase alfa that has been submitted, with previous,s...
(Date:11/24/2009)... , REDWOOD CITY, Calif., Nov. 24 /PRNewswire... ) today announced that Randy Scott, Genomic Healt...nnual Piper Jaffray Health Care Conference in New ...m. ET. ,, To access the live and subsequently ...vestor Relations section of Genomic Health,s websi...
(Date:11/24/2009)... Program Connects Customers wi...es Collected with DNA Genotek Products , ...09 -- DNA Genotek , a leading provider of product...and preparation, today announced its new global pa...ncements for DNA Genotek,s partner community and i...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
... DuPont Applied BioSciences has turned to MB...ing the commercial viability of an important bio-b...n bridging the gap between research and commercial...sed technologies. MBI’s unique “Collab...ddresses technological uncertainties, which impede...
...ec. 2 GeneGo, Inc., the leading systems biology t...ome a certified GeneGo Center of Excellence. Burnh...o GeneGo,s MetaCore data analysis suite, training ...world-class biomedical research facility running m... departments, including research in cancer, stem c...
...ec. 2 Intradigm Corporation, a leading,developer ...apeutics, today,announced the issuance of United S...ositions for Controlling Efficacy of RNA Silencing...al research of Philip Zamore, Ph.D., the,Gretchen ...sor of Biochemistry,& Molecular Pharmacology a...
Other Biology Technology: DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product 2The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 3
(Date:11/26/2009)...RSA (methicillin-resistant Staphylococcus Aureus ...ihilation as low-temperature plasma prototype devi... and unfailing bactericidal cocktails. , Two pro...ent disinfection of healthy skin (e.g. hands and f... can pose a lethal threat; and another to shoot ba...
(Date:11/25/2009)...thens, Ga. Bacteria don,t have easy lives. In add... bugs, they have natural enemies called bacterioph... every two days. , Still, bacteria and another ...overed in extreme environments such as deep-sea vo... because they have a built-in defense system that ...
(Date:11/25/2009)...ADISON, WI, NOVEMBER 25, 2009 Soil is the linchpi... and hydrosphere meet. Despite that, many students...but nothing more. Soil science educators are chall...blic recognize the critical importance of soil in ...oil science and earth science teachers at Universi...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3It's not just dirt! 2Now butterflies are also being counted in China Australia and Israel 9574 1Now butterflies are also being counted in China Australia and Israel 9574 2Now butterflies are also being counted in China Australia and Israel 9574 3Now butterflies are also being counted in China Australia and Israel 9574 4International Robotic Surgery Forum Launches In Chicago 54545 1International Robotic Surgery Forum Launches In Chicago 54545 2International Robotic Surgery Forum Launches In Chicago 54545 3Biopelle Inc Acquires PRESCRIBEDsolutions 5BCUSTOMIZED SKINCARE 5D 28R 29 54541 1Biopelle Inc Acquires PRESCRIBEDsolutions 5BCUSTOMIZED SKINCARE 5D 28R 29 54541 2Biopelle Inc Acquires PRESCRIBEDsolutions 5BCUSTOMIZED SKINCARE 5D 28R 29 54541 3
...y of Pennsylvania researchers have uncovered an im...ses cooperating proteins found on its outer coat t...Further, the studys authors say, they have demonst...n interactions using biomolecular complementation....the National Academy of Sciences, provide a better...
...ong been a staple for people planning their day. N...re working to broaden daily forecasts to include p... reality in some parts of the world. , Some scien...e, global forecasts of air pollution near the grou...ears away. Such a system could prove useful in eff...
...tural climate variations, which tend to involve lo...ve a larger effect on hurricane activity than the ...in this week,s Nature suggests. , In the debate o... is generally assumed that warmer oceans provide a...ent and intensification. However, several other fa...
Other Biology News:Penn researchers shine the light of venus to learn how the herpes virus invades cells 2Air quality forecasts see future in space 2Air quality forecasts see future in space 3Climate's remote control on hurricanes 2
Human HGF, Unconjugated from R&D Systems
Bovine PC-BSA (Bovine Serum Albumin), Unconjugated from Biosearch Technologies
Ral Immunoblot Assay Kit from Upstate
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE) from Molecular Probes (Invitrogen)
Biology Products: